RE:RE:RE:Hey narmac
prophetoffactz wrote: "We need a CEO with a vision, connections and negotiating skills."
Sounds like Rathjen.
She had the connections to Ladenberg Thalmann and got the ball rolling.
Her vision was as big as getting the Former Finance Director of Shire Pharmaceuticals to run the company. He defied anyone to find a company of Biodexa's size with more opportunity. It would no longer be just dependent on licensing but could develop xB3 therapeutics internally on its own. It had a lead glioblastoma drug and xB3 has an affiinity for gioblastoma. Biodexa could also create extended release drugs with Q-Sphera leap-frogging Denali, etc. The world's largest healthcare company is investigating Q-Sphera and xB3. No other company has developed extended release monoclonal antibodies like Q-Sphera, a key area for xB3. Biodexa also attracted a very strong and capable financial backer in Armistice Capital to provide a potential US$20 million cash runway to key hard data catalysts. The company would be listed on NASDAQ and have the scale to interest serious investors on the world stage. Rathjen has negotiated more and bigger deals, evaluations and potential transformative deals than any CEO in BTI's history(Chiesi, J&J, Daiichi, Ellipses, Neuramedy, Oxyrane, Aposense, Cresence, Biodexa).
LOL - oh my goodness (wipes away tears) - you are quite the comedian- seriously, what an absolute joke! DR is none of those things & can really NOT be credited for Chiesi or J&J-Nor should she get credit for failed deals that aren't even happening.
We all know you're a paid shill, an an ineffective one at that.